Iressa and Velcade co-shared 2004 Pharmaceutical Achievement Awards

Published: 2004-09-10 06:56:00

Updated: 2004-09-10 06:56:00

AstraZeneca's Iressa (gefitinib) and Millennium Pharmaceuticals's Velcade (bortezomib) co-shared the Oncology Compound of the Year at the third annual Pharmaceutical Achievement Award held in Boston. The Pharmaceutical Achievement Awards recognizes innovation and individual achievement in a numbe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK